

11th July, 2017

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400001 Scrip Code: BSE - AJANTPHARM 532331	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: NSE AJANTPHARM EQ
---	---

Re: Disclosures under Regulation 30 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

We have to inform that M/s. Ganga Exports, a promoter group entity has sold 27,00,000 equity shares of the company representing 3.07% of paid up capital.

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, please also find enclosed herewith press release being issued in this regard.

Thanking You,

Yours faithfully,



GAURANG SHAH
AVP - Legal &
Company Secretary

Encl.: a/a

Press Release**Promoters Sells Small Stake in Ajanta Pharma**

Mumbai, 11th July, 2017: Mr. Yogesh M. Agrawal, Managing Director of Ajanta Pharma Limited (“APL” or “Company”) has informed the Company that promoters have sold 27,00,000 equity shares in APL, representing about 3.07% of APL's equity shares. Consequent to sale, promoter holding has come down from 73.78% to 70.71% stake in APL.

This sale has been done to provide liquidity to the promoters and the proceeds will be utilized for personal use.

Mr. Yogesh M. Agrawal, Managing Director, Ajanta Pharma Limited, and also a part of the promoter group, said “APL is a standout success and we are immensely proud of our company's journey so far. We believe that we have the right business strategy and management team to deliver our growth aspirations. I am excited to continue to steer APL's next phase of growth.”

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company's products are 1st to market and are leading in their sub-therapeutic segments.

Company's state of the art R&D centres for formulation development and API are located at Mumbai, having a team of 800+ scientists. Company has 7 world class manufacturing facilities located in India and Mauritius.

For last 5 years, company has posted healthy performance with its consolidated total income growing at 21% CAGR and net profit at 46% CAGR.

For more details visit www.ajantapharma.com

For regular updates follow us on twitter– www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331
Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement